Discover trends, market shifts, and competitive outlooks for the asthma drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Asthma Drugs Market Size from 2025 to 2034?

In recent years, the market size for asthma medications has seen robust growth. It’s projected to expand from $23.96 billion in 2024 to $25.17 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.0%. The historical period’s growth can be attributed to environmental factors, a rise in respiratory disorders, changes in lifestyle, and enhancements in healthcare infrastructure.

The market size for asthma medication is projected to experience significant expansion in the upcoming years. An increase to $31.98 billion is anticipated by 2029, with a compound annual growth rate (CAGR) of 6.2%. This anticipated growth during the prediction period is largely due to factors such as escalating levels of air pollution, a surge in the aged population, the rise in health consciousness, evolving trends in personalized medicine, and breakthroughs in biopharmaceuticals. Noteworthy trends during the forecast period include developments in small molecule therapies, home-care solutions for asthma, the use of biomarkers in therapies, advancements in treatments for severe asthma, and partnerships in asthma research.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11924&type=smp

Which Primay Drivers Are Accelerating Growth in the Asthma Drugs Market?

The high occurrence of asthmatic conditions is set to boost the future growth of the asthma drug market. Asthma is a chronic disease characterised by inflammation and swelling of the airways, leading to their narrowing, hindering the passage of air from the nose and mouth to the lungs. Due to the rise in asthma incidences, there has been an increased focus on developing new asthma drugs to treat such conditions. For instance, Asthma + Lung UK, a charity based in England that aids individuals with lung issues, reported that in April 2024, the number of deaths attributed to asthma in England was 1,146 in 2021, but this number jumped to 1,236 in 2022, revealing an alarming upward pattern in deaths related to this condition throughout that year.

Which Primary Segments of the Asthma Drugs Market Are Driving Growth and Industry Transformations?

The asthma drugs market covered in this report is segmented –

1) By Type Of Asthma: Allergic, Non-Allergic

2) By Asthma Trigger Type: Adult-Onset Asthma, Child-Onset Asthma, Cough-Induced Asthma, Exercise-Induced Asthma, Occupational Asthma, Nocturnal Asthma, Steroid-Resistant Asthma

3) By Therapy: Preventive, Curative

4) By Drug Class: Bronchodilators, Monoclonal Antibodies, Anti-Inflammatory Drugs, Combination Drugs

5) By End-User: Asthma Patients, COPD Patients

Subsegments:

1) By Allergic: Inhaled Corticosteroids (ICS), Leukotriene Receptor Antagonists (LTRAs), Monoclonal Antibodies

2) By Non-Allergic: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs), Oral Corticosteroids

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=11924&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Asthma Drugs Market?# Market?

North America was the largest region in the asthma drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the asthma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Asthma Drugs Industry Dynamics?

To improve treatment effectiveness and patient adherence, major firms in the asthma drugs market are concentrating on pioneering innovations, such as fixed-dose combination (FDC) drugs. An FDC drug is a type of medication that combines two or more active constituents into a single dosage form such as a pill, capsule, or inhaler. For example, Glenmark Pharmaceuticals, a pharmaceutical company based in India, introduced Indamet, a fixed-dose combination (FDC) drug in India for patients with uncontrolled asthma in June 2022. This innovative therapy pairs Indacaterol, a long-lasting beta-agonist, and Mometasone Furoate, an inhaled corticosteroid. It is available in a variety of strengths, including combinations of Indacaterol 150 mcg and Mometasone at 80 mcg, 160 mcg, and 320 mcg. Indamet, developed for once-daily application, is aimed at adults and adolescents aged 12 and above.

View the full report here:

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

What Parameters Are Used to Define the Asthma Drugs Market?

Asthma refers to a chronic lung disease that is caused by the inflammation and tightening of muscles around the airways, which makes patients suffer from effective breathing. This is caused when the airways get narrow, swollen, and blocked by excess mucus. Asthma drugs play a crucial role in managing asthma.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11924

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model